No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
107 |
4. Check minimum number of eventsNone |
107 |
5. Include endpointsNone |
107 |
6. Filter based on genotype QC (FinnGen only) |
107 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF5
Similar endpoints
↥List of similar endpoints to
Drug-induced dystonia
based on the number of shared cases.
Similar with more cases:
- Dystonia
- Extrapyramidal and movement disorders
- Neurological diseases
- Neurological diseases, wide definition
- Any operation in hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 816 | 453 | 361 |
| Only index persons | 739 | 416 | 323 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.02 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 48.80 | 52.93 | 43.66 |
| Only index persons | 46.80 | 49.61 | 43.17 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 107 | 65 | 42 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 46.30 | 48.07 | 43.56 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 100
- Matched controls
- 999
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G24.0
ICD-10 Finland
Drug-induced dystonia
+∞
144.2
100
*
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
40.1
40.7
52
26
N05AH03
ATC
olanzapine; systemic
26.1
30.7
44
29
N04AA02
ATC
biperiden; systemic
63.2
30.1
34
8
N05AX08
ATC
risperidone; systemic
28.0
29.5
41
24
N05AH04
ATC
quetiapine; oral
12.0
26.3
58
103
N05AX12
ATC
aripiprazole; systemic
35.4
25.0
32
13
F29
ICD-10 Finland
Unspecified nonorganic psychosis
42.0
24.5
30
10
N03AE01
ATC
clonazepam; systemic
20.0
22.8
35
26
N03AG01
ATC
valproic acid; systemic, rectal
16.5
20.6
34
30
N05AH02
ATC
clozapine; systemic
42.0
19.0
23
7
N05BA01
ATC
diazepam; systemic, rectal
9.2
17.7
41
70
F25.9
ICD-10 Finland
Schizoaffective disorder, unspecified
77.2
17.4
19
*
N05AA02
ATC
levomepromazine; systemic
24.4
16.5
23
12
G24.9
ICD-10 Finland
Dystonia, unspecified
72.2
16.4
18
*
N05AD01
ATC
haloperidol; systemic
23.7
15.0
21
11
N05BA06
ATC
lorazepam; systemic, sublingual
14.6
13.7
23
20
N06AX11
ATC
mirtazapine; oral
5.1
13.2
56
198
R56.8
ICD-10 Finland
Other and unspecified convulsions
14.5
13.1
22
19
F20.00
ICD-10 Finland
Paranoid schizophrenia continuous
37.6
13.0
16
5
F20.9
ICD-10 Finland
Schizophrenia, unspecified
31.3
12.5
16
6
N06AB04
ATC
citalopram; systemic
5.5
12.5
44
125
T36
ICD-10 Finland
Poisoning by systemic antibiotics
12.5
12.3
22
22
P72
ICPC
Schizophrenia
34.8
12.0
15
5
N05BA04
ATC
oxazepam; oral
5.1
12.0
47
149
X69
ICD-10 Finland
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
14.3
11.4
19
16
N05AB03
ATC
perphenazine; systemic, rectal
13.5
11.1
19
17
C07AA05
ATC
propranolol; systemic
5.5
11.0
37
97
N05BE01
ATC
buspirone; oral
16.8
11.0
17
12
G24.3
ICD-10 Finland
Spasmodic torticollis
122.3
10.6
11
*
N05AL01
ATC
sulpiride; systemic
36.9
10.6
13
*
F20.30
ICD-10 Finland
Undifferentiated schizophrenia continuous
26.8
10.6
14
6
N05CD07
ATC
temazepam; oral
8.0
10.4
24
38
N05AN01
ATC
lithium; oral
19.3
10.2
15
9
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
6.4
10.2
28
57
N07BB01
ATC
disulfiram; oral
13.4
10.0
17
15
N05AF03
ATC
chlorprothixene; systemic
17.4
9.9
15
10
SPAT1254
SPAT
Administration of medicine
5.9
9.7
29
65
N06AB03
ATC
fluoxetine; oral
5.3
9.4
31
78
N05AE04
ATC
ziprasidone; systemic
55.0
8.8
10
*
F31.7
ICD-10 Finland
Bipolar affective disorder, currently in remission
18.4
8.8
13
8
F25.10
ICD-10 Finland
Schizoaffective syndrome, depressive type with only concomitant bipolar and schizophrenic symptoms
98.0
8.6
9
*
F31.5
ICD-10 Finland
Bipolar affective disorder, current episode severe depression with psychotic symptoms
98.0
8.6
9
*
G72.8
ICD-10 Finland
Other specified myopathies
+∞
8.4
8
*
F31.6
ICD-10 Finland
Bipolar affective disorder, current episode mixed
36.6
8.2
10
*
N06AB06
ATC
sertraline; oral
5.3
8.2
26
62
F31.9
ICD-10 Finland
Bipolar affective disorder, unspecified
12.3
8.1
14
13
F10.1
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Harmful use
7.9
8.0
18
27
N06AX03
ATC
mianserin; oral
12.2
7.5
13
12
G24.8
ICD-10 Finland
Other dystonia
86.2
7.5
8
*
AA1AD
NOMESCO Finland
CT of head and brain
4.1
7.4
31
98
AA400
NOMESCO Finland
Electroconvulsive therapy
+∞
7.4
7
*
P99
ICPC
Psychological disorders other
13.4
7.3
12
10
N05AA01
ATC
chlorpromazine; systemic, rectal
32.6
7.3
9
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.8
7.1
33
114
F20.39
ICD-10 Finland
Undifferentiated schizophrenia UNS
43.1
6.9
8
*
F60.30
ICD-10 Finland
Emotionally unstable personality disorder, impulsive
11.2
6.7
12
12
N05AC02
ATC
thioridazine; oral
15.7
6.5
10
7
F22.0
ICD-10 Finland
Delusional disorder
74.4
6.5
7
*
F25.20
ICD-10 Finland
Schizoaffective syndrome, mixed type with only concomitant bipolar and schizophrenic symptoms
74.4
6.5
7
*
N05AE05
ATC
lurasidone; oral
74.4
6.5
7
*
IAA01
NOMESCO Finland
Assessment of need for psychiatric treatment
12.2
6.5
11
10
N05AF05
ATC
zuclopenthixol; systemic
28.7
6.3
8
*
F32.3
ICD-10 Finland
Severe depressive episode with psychotic symptoms
28.7
6.3
8
*
G25.9
ICD-10 Finland
Extrapyramidal and movement disorder, unspecified
+∞
6.3
6
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
4.6
6.2
21
54
188
Kela drug reimbursment
Psychosis requiring demanding treatment
16.3
6.0
9
6
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
16.3
6.0
9
6
F33.10
ICD-10 Finland
Recurrent depression, moderate episode without somatic syndrome
5.9
6.0
16
31
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
15
11
15.70
16.25
7.7
19.5
889.3
756.0
nmol/l
0.26
15
11
56
263
3.37
8.83
2.4
2.4
49.1
56.6
u/l
0.61
51
243
48
207
3.39
8.67
3.5
3.9
15.2
11.1
mg/mmol
0.17
30
129
68
370
3.30
8.20
8.5
6.3
1.2
1.2
mmol/l
0.17
63
311
75
440
3.36
7.81
4.8
6.0
10.0
11.4
umol/l
0.63
70
417
29
97
3.73
7.64
2.2
1.9
—
—
—
0
0
16
34
5.36
7.44
1.6
1.3
—
—
—
0
0
61
327
3.01
7.28
3.9
4.1
35.2
36.3
g/l
0.61
56
313
38
161
3.11
6.82
1.5
1.6
0.9
0.9
mg/l
0.08
27
124
22
72
3.59
5.90
1.7
1.8
—
—
—
0
0
22
72
3.59
5.90
1.8
1.8
—
—
—
0
0
31
128
3.00
5.71
1.9
1.4
1335.6
1231.1
nmol/l
0.25
25
101
56
316
2.62
5.65
2.3
1.7
93.6
102.2
pmol/l
0.62
33
155
16
47
3.83
4.97
1.3
1.5
—
—
—
0
0
86
632
2.84
4.58
3.8
3.8
11.7
9.3
mm/h
0.61
80
577
48
272
2.39
4.56
2.5
2.6
—
—
—
0
0
56
342
2.34
4.46
2.6
2.2
76.9
73.6
nmol/l
0.25
51
299
20
75
3.05
4.28
2.0
2.2
362.9
355.6
nmol/l
0.07
20
70
11
28
4.26
4.09
3.5
2.7
51.4
53.0
%
0.06
11
28
9
14
6.91
4.07
1.3
1.2
—
—
—
0
0
9
14
6.91
4.07
1.3
1.2
—
—
—
0
0
84
645
2.41
3.49
5.0
2.8
42.5
45.7
u/l
0.22
78
621
29
146
2.35
3.48
2.3
1.6
533.2
461.6
pmol/l
0.56
29
125
102
895
3.99
3.22
21.2
11.1
24.5
20.0
mg/l
0.82
84
669
11
36
3.29
2.90
3.7
2.4
124.2
124.0
g/l
0.01
11
36
20
97
2.31
2.57
7.2
5.8
—
—
—
0
0
5
7
7.42
2.57
4.4
1.0
—
—
—
0
0
44
289
1.89
2.54
5.7
3.0
19.3
51.1
ng/l
0.93
28
174
21
110
2.13
2.25
2.3
2.2
0.8
2.8
e6/l
—
10
58
22
118
2.09
2.22
2.3
2.2
2.2
1.0
e6/l
0.51
12
67
35
223
1.85
2.17
2.6
2.3
0.4
0.3
e6/l
0.17
25
166
23
127
2.03
2.15
5.0
3.2
37.5
217.0
ng/l
0.81
15
90
7
20
3.67
2.09
1.1
1.3
—
—
—
0
0
8
28
3.00
1.90
1.3
1.1
—
—
—
0
0
8
28
3.00
1.90
1.3
1.1
—
—
—
0
0
55
414
1.68
1.85
4.4
3.2
0.0
0.0
estimate
—
7
79
13
62
2.25
1.74
3.5
2.9
73.0
70.5
ml/min/173m2
—
7
22
94
830
2.09
1.72
15.5
10.7
87.5
87.3
ml/min/173m2
0.03
74
655
7
25
2.92
1.68
3.4
1.9
—
—
—
0
0
30
198
1.72
1.61
1.4
1.3
1.4
1.1
u/ml
—
10
61
12
58
2.20
1.56
2.0
2.2
1.5
5.9
ug/l
—
7
53
54
420
1.58
1.50
4.6
3.3
0.0
0.0
estimate
—
7
75
44
328
1.58
1.46
5.1
3.3
—
—
—
0
0
94
845
1.93
1.40
6.2
3.9
6.0
5.8
mmol/l
0.70
88
779
0
41
0.00
1.34
0.0
1.6
—
—
—
0
0
53
419
1.52
1.33
6.4
4.5
0.0
0.0
estimate
—
7
79
89
793
1.73
1.29
8.5
4.9
39.2
38.8
mmol/mol
0.12
84
742
8
39
2.13
1.18
3.1
6.2
1.2
1.5
%
—
8
39
5
20
2.57
1.16
4.2
2.0
—
—
—
0
0
5
20
2.57
1.16
4.6
2.3
—
—
—
0
0
0
36
0.00
1.16
0.0
1.5
—
—
—
0
0
0
36
0.00
1.16
0.0
1.5
—
—
—
0
0
0
36
0.00
1.16
0.0
1.5
—
—
—
0
0
7
30
2.42
1.14
1.4
1.3
—
—
—
0
0
23
155
1.62
1.13
1.2
1.3
1.2
8.3
u/ml
—
8
64
7
36
2.01
0.99
1.6
2.1
4.0
1.9
mg/l
—
7
26
8
42
1.98
0.91
2.4
4.9
27.9
25.1
mmol/l
—
8
42
5
100
0.48
0.82
1.6
1.7
—
—
—
0
0
94
879
1.57
0.75
5.6
4.0
4.4
4.7
mmol/l
2.81
89
811
8
50
1.65
0.63
1.3
1.3
—
—
—
0
0
0
23
0.00
0.59
0.0
2.4
—
163.4
—
0
23
6
35
1.76
0.59
1.5
1.3
—
—
—
0
0
90
846
1.40
0.57
5.1
3.6
1.6
1.3
mmol/l
2.32
83
772
28
226
1.32
0.56
5.0
3.3
0.0
0.0
estimate
—
7
78
93
880
1.43
0.56
5.5
4.0
1.3
1.5
mmol/l
3.85
87
806
94
893
1.43
0.53
6.0
4.4
2.5
2.8
mmol/l
2.79
87
818
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
1.1
—
0
6
69
643
1.21
0.36
3.6
3.3
—
—
—
0
0
22
184
1.25
0.34
4.0
2.0
—
—
—
0
0
13
101
1.33
0.33
3.1
4.2
32.9
32.3
%
—
8
64
7
52
1.37
0.32
1.1
1.0
—
—
—
0
0
8
63
1.29
0.28
1.5
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
5.1
—
116.4
—
0
10
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.9
—
13.7
—
0
12
14
165
0.83
0.21
1.4
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
6
75
0.79
0.16
3.2
3.6
—
—
—
0
0
9
80
1.14
0.15
1.6
2.0
—
—
—
0
0
37
395
0.90
0.15
5.2
3.9
—
—
—
0
0
5
45
1.12
0.10
5.8
2.0
36.1
39.3
u/l
—
5
40
5
48
1.04
0.09
2.0
2.0
—
—
—
0
0
14
129
1.10
0.06
2.1
2.1
—
—
—
0
0
19
197
0.96
0.01
1.5
1.5
—
—
—
0
0
14
137
1.03
0.00
2.4
2.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
3.0
—
892.5
—
0
6
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
208.2
—
0
6
Mortality – FinRegistry
↥Association
Association between endpoint DRUGADVERS_DYSTON and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| DRUGADVERS_DYSTON | 2.337 [1.66, 3.29] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.327 |
During the follow-up period (1.1.1998 — 31.12.2019), 94 out of 404 females with DRUGADVERS_DYSTON died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| DRUGADVERS_DYSTON | 3.612 [2.33, 5.59] | < 0.001 |
| Birth year | 0.987 [0.98, 1.0] | 0.009 |
During the follow-up period (1.1.1998 — 31.12.2019), 88 out of 311 males with DRUGADVERS_DYSTON died.
Mortality risk
Mortality risk for people of age
years, who have DRUGADVERS_DYSTON.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.25% | 0.727% |
| 5 | 1.384% | 4.207% |
| 10 | 3.357% | 10.293% |
| 15 | 6.468% | 18.763% |
| 20 | 11.315% | 30.864% |
Relationships between endpoints
↥Index endpoint: DRUGADVERS_DYSTON – Drug-induced dystonia
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data